Skip to content

Galenagen Receives Patent for Remote Monitoring of Parkinson’s Disease

16 September, 2020

Rye Brook, NY, September 16, 2020 – Galenagen, LLC, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,776,453 relating to remote monitoring of Parkinson’s Disease.

Galenagen’s patent is directed to methods of employing remote data gathering and monitoring for diagnosing, staging and treatment of Parkinson’s Disease, movement and neurological disorders and chronic pain.  The technology will help facilitate early Parkinson’s staging and ongoing monitoring of a patient’s condition.

“Given the devastating impact of Parkinson’s on patients, their families and the healthcare system, improving access to data that can inform physicians should improve care,” said Dr. Joan Fallon, Curemark’s CEO and Founder.  “This should be a more equitable way to receive care and have a patient’s condition monitored for changes especially for those who live in rural areas or find travel impacted by the disease.”

Galenagen is a wholly-owned subsidiary of Curemark, LLC, a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Galenagen LLC is focused on antibacterial and antiviral treatments as well as medical devices.  Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of autism, ADHD, addiction, schizophrenia and Parkinson’s disease. For additional information, please visit our website at or  or follow @Curemark on Twitter.


Safe Harbor

This press release includes both historical facts and forward-looking statements.  All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934.  In some cases, forward-looking statements can be identified by words such as “may,” “will,” “should,” “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “predict,” “potential,” the negative of such words, variations of such words and similar expressions, although not all forward-looking statements contain these identifying words.

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.  These risks and uncertainties include, among other things, uncertainties inherent in (i) research and development, (ii) the building of Galenagen, LLC’s patent portfolio and protection of its intellectual property, (iii) the conduct of clinical trials, (iv) obtaining the requisite approval of regulatory authorities to market and sell Galenagen LLC’s product candidates, (v) decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of Galenagen LLC’s product candidates, and (vi) competitive developments.

Readers should not place undue reliance on any forward-looking statements, which are based on Galenagen, LLC’s current expectations of future events and speak only as of the date they are made.  Except as may be required by law, Galenagen, LLC undertakes no obligation to update any forward-looking statements contained in this press release to reflect any change in Galenagen, LLC’s expectations or any change in information, events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.